HHV-8–Associated Multicentric Castleman's Disease in HIV-Negative Patient: A Novel Therapy for an Orphan Disease

Abstract

A case of multicentric Castleman's disease in an HIV− human herpesvirus 8+ patient who was successfully managed with concurrent bortezomib and ganciclovir is presented.

Co-existence of multicentric Castleman′s disease and Kaposi′s sarcoma

“…Notably, MCD has been reported in adults usually before age 30[ 3 ] and shows an association with HHV-8 and HIV infections. [ 11 ] In contrast, our patient was a 77-year-old man and compared with the prior literature findings, he had HHV-8 and HIV-negative serology. Co-incidence of MCD with KS in our case report can be interpreted that MCD may be complicated by KS or the latter is a manifestation of MCD.…”

Durable remission of both multicentric Castleman's disease and Kaposi's sarcoma with valganciclovir, rituximab and liposomal doxorubicin in an HHV-8-positive, HIV-negative patient

“…Broad‐spectrum antiviral agents directed against HHV‐8 are not part of the routine management of multicentric Castleman's disease or Kaposi's sarcoma due to lack of proven benefit. Only a few reports of this treatment approach exist, mostly in HIV‐positive patients; however, even responses considered durable are reported as lasting only 3–18 months . In all of these cases, antiviral treatment was ceased upon resolution of multicentric Castleman's disease recurrence, except for one case where continuation was not explicitly stated.…”

Castleman disease and lymphocytic interstitial pneumonia: a complex diagnostic and management challenge

“…Reports of Bortezimib inducing sustained remission in CD exist 6 . Small prospective studies in HIV-positive CD demonstrate Rituximab maintains sustained response either alone or following chemotherapy 7 .…”